138 related articles for article (PubMed ID: 35968588)
21. Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
Fiorcari S; Benatti S; Zucchetto A; Zucchini P; Gattei V; Luppi M; Marasca R; Maffei R
Leukemia; 2019 May; 33(5):1278-1302. PubMed ID: 30659236
[No Abstract] [Full Text] [Related]
22. Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
Raponi S; Del Giudice I; Ilari C; Cafforio L; Messina M; Cappelli LV; Bonina S; Piciocchi A; Marinelli M; Peragine N; Mariglia P; Mauro FR; Rigolin GM; Rossi F; Bomben R; Dal Bo M; Del Poeta G; Diop F; Favini C; Rossi D; Gaidano G; Cuneo A; Gattei V; Guarini A; Foá R
Br J Haematol; 2019 Apr; 185(1):156-159. PubMed ID: 29785734
[No Abstract] [Full Text] [Related]
23. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.
Brachtl G; Piñón Hofbauer J; Greil R; Hartmann TN
Ann Hematol; 2014 Mar; 93(3):361-74. PubMed ID: 24288111
[TBL] [Abstract][Full Text] [Related]
24. Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Poeta GD; Gaidano G; Rossi FM; Bulian P; Zucchetto A; Gattei V
Curr Cancer Drug Targets; 2016; 16(8):659-668. PubMed ID: 27514846
[TBL] [Abstract][Full Text] [Related]
25. Association of CD49d expression with clinicopathological features of chronic lymphocytic leukemia patients in the Iranian population.
Nematollahi P; Shakery M; Kefayat A; Goli P
Int J Physiol Pathophysiol Pharmacol; 2020; 12(1):32-39. PubMed ID: 32211120
[TBL] [Abstract][Full Text] [Related]
26. Flow Cytometric Expression of CD49d in Newly Diagnosed Chronic Lymphocytic Leukemia and Its Correlation with Established Prognostic Markers.
Kunnumbrath A; Singh N; Gupta AK; Chowdhury N; Nath UK; Chandra H
J Lab Physicians; 2022 Dec; 14(4):435-442. PubMed ID: 36531546
[No Abstract] [Full Text] [Related]
27. Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Del Poeta G; Gaidano G; Rossi FM; Zucchetto A; Gattei V
Semin Hematol; 2014 Jul; 51(3):168-76. PubMed ID: 25048781
[TBL] [Abstract][Full Text] [Related]
28. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.
Rossi D; Zucchetto A; Rossi FM; Capello D; Cerri M; Deambrogi C; Cresta S; Rasi S; De Paoli L; Bodoni CL; Bulian P; Del Poeta G; Ladetto M; Gattei V; Gaidano G
Haematologica; 2008 Oct; 93(10):1575-9. PubMed ID: 18641015
[TBL] [Abstract][Full Text] [Related]
29. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
Kriston C; Plander M; Márk Á; Sebestyén A; Bugyik E; Matolcsy A; Barna G
Ann Hematol; 2018 Nov; 97(11):2145-2152. PubMed ID: 29955944
[TBL] [Abstract][Full Text] [Related]
30. Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia.
Finn WG; Singleton TP; Schnitzer B; Ross CW; Stoolman LM
Hum Pathol; 2001 Jan; 32(1):66-73. PubMed ID: 11172297
[TBL] [Abstract][Full Text] [Related]
31. Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications.
Zucchetto A; Tissino E; Chigaev A; Hartmann TN; Gattei V
Methods Mol Biol; 2019; 1881():101-112. PubMed ID: 30350200
[TBL] [Abstract][Full Text] [Related]
32. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance.
Zucchetto A; Bomben R; Dal Bo M; Bulian P; Benedetti D; Nanni P; Del Poeta G; Degan M; Gattei V
Leukemia; 2006 Mar; 20(3):523-5; author reply 528-9. PubMed ID: 16408095
[No Abstract] [Full Text] [Related]
33. Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis.
Tooze JA; Hamzic E; Willis F; Pettengell R
Cancer Genet; 2017 Dec; 218-219():20-38. PubMed ID: 29153094
[TBL] [Abstract][Full Text] [Related]
34. CD43 and CD49d from the B-Cell Chronic Lymphoproliferative Disorders Diagnostic Panel Are Useful to Detect Erythroid Dysplasia.
Oliveira M; Laranjeira P; Fortuna M; Bártolo R; Ribeiro A; Santos M; Cortesão E; Marques G; Sarmento-Ribeiro AB; Vitória H; Ribeiro L; Paiva A
Cytometry B Clin Cytom; 2019 Sep; 96(5):417-425. PubMed ID: 31157955
[TBL] [Abstract][Full Text] [Related]
35. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
36. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia.
Szenes E; Härzschel A; Decker S; Tissino E; Pischeli J; Gutjahr JC; Kissel S; Pennisi S; Höpner JP; Egle A; Zaborsky N; Dierks C; Follo M; Chigaev A; Zucchetto A; Greil R; Gattei V; Hartmann TN
Leukemia; 2020 Sep; 34(9):2498-2502. PubMed ID: 32086446
[No Abstract] [Full Text] [Related]
37. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
38. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
39. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9.
Buggins AG; Levi A; Gohil S; Fishlock K; Patten PE; Calle Y; Yallop D; Devereux S
Br J Haematol; 2011 Jul; 154(2):216-22. PubMed ID: 21569005
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of prognostic variables in chronic lymphocytic leukemia and association with disease stage.
Attia HRM; Ibrahim MH; El-Aziz SHA; Abdelrahman AH; Sobeih ME; Hagag HAA; Yassa ME; Osman RA; Rawi R; El-Dayem OYA; Elsharkawi N; Abdelfattah R; Hassan NM
Mol Clin Oncol; 2021 May; 14(5):100. PubMed ID: 33796290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
